Headquartered in 79 New Oxford Street, London Fiscal year ends December NYSE: GSK gsk.com
GSK plc is a global biopharma company focused on uniting science, technology, and talent to get ahead of disease. The company operates through three commercial segments: Specialty Medicines (HIV treatments via majority-owned ViiV Healthcare, Respiratory/Immunology/Inflammation therapies, and Oncology), Vaccines (including shingles vaccine Shingrix, meningitis vaccines, and RSV vaccine Arexvy), and General Medicines (inhaled respiratory products including Trelegy, dermatology, and antibiotics). GSK has 57 medicines and vaccines in clinical development across 76 projects, with 16 assets in phase III or under regulatory review. The company's pipeline spans chronic hepatitis B (bepirovirsen), MASH (efimosfermin), chronic cough (camlipixant), multiple myeloma (Blenrep), various cancers (Jemperli, antibody-drug conjugates Ris-Rez and Mo-Rez), and next-generation HIV treatments. GSK holds a 78.3% economic interest in ViiV Healthcare, with Shionogi holding 21.7% following the Q1 2026 restructuring that eliminated Pfizer's stake. The company is listed on both the London Stock Exchange and the New York Stock Exchange. Updated
Cerebras stock cratered to a post-IPO low while rivals like NVIDIA and AMD surged, yet one of the world's largest banks just doubled down with a price target that implies the market…
The shingles vaccine costs nothing under Medicare Part D, yet thousands of beneficiaries walk out of their doctor's office owing hundreds of dollars for the exact same shot. The billing system has…
GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real…
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to…
GSK has handed investors a remarkable run. Over the past year, the stock climbed roughly 44% from $37.79 to $54.51. If you watched from the sidelines, the question now is painfully familiar:…
William Temple Of everything C3.ai (NYSE: AI) | AI Price Prediction has promised investors over the years, tonight’s revenue number is the one that actually has to deliver. Not the deal count, not the…
Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.
Live Updates Nvidia Drives Stock Market Higher4:25pm ETStrong performance from Dow Jones Industrial Average component company Nvidia (Nasdaq: NVDA | UNH Price Prediction) helped to drive the index higher Tuesday. Nvidia stock…
Merck just rewarded its shareholders again with a dividend hike. This Dow Jones industrial stock has come with a quarterly dividend for almost two decades.
Stock splits are typically viewed as bullish indicators that a company sees more growth is on the horizon. Although nothing fundamental changes about the business, making the share price cheaper allows more…
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the growth various weight loss drugs have seen is notable, with GLP-1 agonists like Ozempic, Wegovy,…
The tech stock selloff in July surprised the market but not those investors who were paying attention. As far back as April, Goldman Sachs (NYSE:GS | GS Price Prediction) warned of the…
Investors have been on a roller coaster ride for the past four years and the stock market may be heading into another big loop higher. Federal Reserve chairman Jay Powell gave his…
Private healthcare sure does seem to be working well in America, doesn’t it? With skyrocketing healthcare costs with diminishing returns, a lower life expectancy, unofficial waitlists, and absurdly high mortality rates for…
GSK plc is a global biopharma company focused on uniting science, technology, and talent to get ahead of disease.
24/7 Wall St.'s 12-month price target for GSK is $59.50, rated Buy. The Wall Street consensus target is $59.33. GSK price prediction →
